Needham & Company Maintains a 'Hold' on Cubist Pharmaceuticals (CBST); 4Q11 Review. U.S. Cubicin Sales Guidance for 2012 In-line with Our Expectations
CBST Hot Sheet
Rating Summary:6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
Needham & Company maintains a 'Hold' on Cubist Pharmaceuticals (NASDAQ: CBST).
Needham analyst says, "Cubist reviewed corporate goals for 2012 and provided financial guidance for the year in a quarterly conference call yesterday. Management guided for $770-795M in 2012 U.S. Cubicin sales, bracketing our expectations coming into the call, but somewhat under the $794M consensus figure. Cubist continues to execute commercially with Cubicin and we expect this to continue in 2012. Nevertheless, we maintain our rating, awaiting clarity on CXA-201 development in HAPB/VABP, a challenging indication. Other than trial initiations, we expect minimal pipeline news flow this year. We expect the stock to perform in-line with the market."
For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $40.40 yesterday, with a 52 week range of $20.95-$42.10.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Needham analyst says, "Cubist reviewed corporate goals for 2012 and provided financial guidance for the year in a quarterly conference call yesterday. Management guided for $770-795M in 2012 U.S. Cubicin sales, bracketing our expectations coming into the call, but somewhat under the $794M consensus figure. Cubist continues to execute commercially with Cubicin and we expect this to continue in 2012. Nevertheless, we maintain our rating, awaiting clarity on CXA-201 development in HAPB/VABP, a challenging indication. Other than trial initiations, we expect minimal pipeline news flow this year. We expect the stock to perform in-line with the market."
For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.
Shares of Cubist Pharmaceuticals closed at $40.40 yesterday, with a 52 week range of $20.95-$42.10.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Barclays Maintains an 'Equalweight' on J. C. Penney (JCP); Slashing PT on Disappointing Results
- Goldman Sachs Boosts Target on Williams-Sonoma (WSM) On Signs of Stabilization
- Nomura Securities Raises PT and Estimates on PetSmart (PETM) After Good Q1
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & Company, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
